A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
Wall Street Journal (04/19/99) P. B2;
Johannes, Laura
The U.S. Food and Drug Administration granted on Friday marketing authorization to Vertex Pharmaceuticals for Agenerase, the fifth drug targeting HIV's protease enzyme that has been approved for the treatment of AIDS. Vertex developed the drug, which will be
marketed by Glaxo Wellcome, using technology licensed from Monsanto's G.D. Searle unit. One advantage of Agenerase over other approved protease drugs is that patients need take it only twice a day, rather than three times a day; but users must consume eight pills of Agenerase at each sitting, compared to two to six when using the other drugs.
The CDC National Center for HIV, STD, and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies,
such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases, and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be
cited as the source of the information.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
Email
Print-Friendly
Glossary
